Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05211570 · ClinicalTrials.gov registry record · Phase 1
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, sponsored by AB Science.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 10
- Study locations
NCT05211570: Recruiting Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, sponsored by AB Science.
NCT05211570 is a Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory that is actively recruiting participants, run by AB Science. The registered enrollment target is 78 participants, above the 55-participant average among 16 other Acute Myeloid Leukemia, in Relapse trials with a reported enrollment target (42% higher). The trial reports 10 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05211570, a Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, is actively recruiting participants, sponsored by AB Science.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.
Primary Outcome
Identification of the Maximal Tolerated Dose for different dosing schedules
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG AB8939
Study Locations (10)
Other
- Institut Paoli Calmettes - Marseille
- National and Kapodistrian University of Athens NKUA · Department of Hematology and Bone marrow Transplantation Unit - Athens
- General University Hospital of Alicantet (Hospital General Universitario Dr. Balmis de Alicante) - Alicante
- Hospital San Pedro de Alcantara - Cáceres
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Universitario Quirónsalud - Madrid
- MD Anderson Cancer Center Madrid - Madrid
- Clínica Universidad de Navarra - Pamplona
- Virgen del Rocío University Hospital (Hospital Universitario Virgen del Rocío) - Seville
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT05211570 shows while recruiting
NCT05211570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, above the 55-participant average among 16 other Acute Myeloid Leukemia, in Relapse trials with a reported enrollment target (42% higher).
The record links to 3 conditions, with Acute Myeloid Leukemia, in Relapse appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT05211570 lists 10 locations in 2 states (Other, Texas).
Frequently Asked Questions
What is clinical trial NCT05211570 about?
NCT05211570 is a clinical study titled "AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia". The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.
What is the current status of trial NCT05211570?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2022-06-01. Estimated completion is 2026-12.
What conditions does trial NCT05211570 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome/Acute Myeloid Leukemia.
What interventions are being tested in trial NCT05211570?
The interventions under investigation include: Venetoclax (DRUG), AB8939 (DRUG).
Who is sponsoring clinical trial NCT05211570?
This trial is sponsored by AB Science, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05211570 being conducted?
This trial has 10 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia, in Relapse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05211570's enrollment target sits among peer trials
78 2nd of 16 the highest of 16 other Acute Myeloid Leukemia, in Relapse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia, in Relapse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
RECRUITING · Phase 1
-
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
RECRUITING · Phase 1
-
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RECRUITING · Phase 1
-
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Venetoclax to Augment Epigenetic Modification and Chemotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI